LEON and Harro Höfliger Announce Strategic Collaboration for Global Distribution and After-Sales Service of Nanoencapsulation Equipment

Planegg, Allmersbach im Tal (Germany), February 19th 2026

leon-nanodrugs GmbH (LEON), a leading developer of advanced nanoencapsulation technology and equipment, and Harro Höfliger, a global expert in pharmaceutical engineering and GMP-compliant production, announced a strategic collaboration to expand worldwide access to LEON’s FR-JET® technology and portfolio of equipment. Under the agreement, Harro Höfliger becomes a non-exclusive global authorized commercialization and service partner for LEON’s products.

 

Through this partnership, customers gain access to comprehensive global service and support, leveraging Harro Höfliger’s decades of experience in GMP-compliant production. LEON’s game-changing equipment is now available worldwide, and worldwide after-sales service is guaranteed. They also benefit from scalable deployment solutions, enabling a seamless transition from early-stage development to full commercial supply. At the same time, LEON continues to provide agility and innovation, ensuring that its cutting-edge technologies are paired with the backing of a major industrial partner.

 

“This partnership represents a major step forward for LEON, enabling us to bring our innovative nanoencapsulation solutions to a global audience while maintaining our commitment to scientific excellence and technology leadership,” said Dr. Wolfgang Hofmann, CEO of LEON.

 

Thomas Weller, CEO at Harro Höfliger, adds: “Driving innovation in pharmaceutical manufacturing is at the heart of this collaboration. By pairing LEON’s pioneering nanoencapsulation technology with Harro Höfliger’s expertise in GMP production solutions, we reaffirm our role as a trusted partner for our customers and provide solutions to scale the manufacturing of advanced therapies efficiently and reliably.”

 

The collaboration is expected to generate significant commercial impact and growth potential for both companies. By combining LEON’s innovative technology with Harro Höfliger’s global reach, GMP expertise, and international sales and service network, the partnership is positioned to accelerate market penetration, improve the customer experience, and unlock substantial growth opportunities worldwide.

 

READ THE FULL PRESS RELEASE

About LEON

Based in Planegg/Munich, leon-nanodrugs GmbH is a pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs).

The company leverages its proprietary FR-JET®  technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services.

LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com